ADCs in Lung Cancer: A Year in Review

Released:	December 13, 2024
Expires:	December 13, 2025
Estimated Completion Time:	1 hour

Target Audience

This activity is intended for oncologists and other healthcare professionals who provide care for patients with lung cancer.

Overview

This Expert Exchange video webcast provides a year-in-review of the rapidly-changing landscape for antibody-drug conjugates in the treatment of lung cancer.

Educational Objectives

Upon completion of this activity, participants should be able to:

• Review the evolving clinical data for antibody drug conjugates (ADC’s) for the treatment of non-small cell lung cancer (NSCLC).
• Identify the role of newly developed ADC’s in the treatment of NSCLC.
• Compare toxicity profiles of ADC’s used for the treatment of NSCLC.

Faculty

Benjamin P. Levy, MD
Associate Professor of Oncology
Clinical Director, Sidney Kimmel Cancer Center
Johns Hopkins University

Stephen V. Liu, MD
Associate Professor of Medicine
Director of Thoracic Oncology and Director of Developmental Therapeutics
Lombardi Comprehensive Cancer Center of Georgetown University

Financial Support

This activity is supported by an independent educational grant from Daiichi Sankyo, Inc. and AstraZeneca

Providers

Jointly provided by Partners for Advancing Clinical Education (PACE) and Novus Medical Education.

Accreditation Statement

Credit Designation for Physicians

PACE designates this enduring material for a maximum of 0.5  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships. The directors, planners, managers and reviewers of this activity, both for PACE and Novus, have no relevant financial relationship(s) to disclose with ineligible companies.

Dr. Levy
Advisor/Consultant: AstraZeneca, Daiichi Sankyo, Gilead, Johnson & Johnson, Novartis, Pfizer
Research Support: AstraZeneca, Johnson & Johnson

Dr. Liu
Advisor/Consultant: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Candel Therapeutics, Catalyst, Daiichi Sankyo, Genentech, Gilead, Guardant Health, Janssen, Jazz Pharmaceuticals, Merck, Merus, Mirati, Novartis, OSE Immunotherapeutics, Pfizer, RAPT, Regeneron, Revolution Medicines, Roche, Sanofi, Takeda, Yuhan
Research Support: AbbVie, Alkermes, AstraZeneca, Elevation Oncology, Ellipses, Genentech, Gilead, Merck, Merus, Nuvalent, OSE Immunotherapeutics, Puma, RAPT, Turning Point Therapeutics

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

Method of Participation

There are no fees for participating and receiving CME credit for this activity. To claim credit, participants must complete the following:

1. Review the target audience, accreditation information, learning objectives and faculty disclosures.
2. Complete the pre-test (if one exists).
3. View and digest the educational content in its entirety.
4. Complete the post-test and activity evaluation.
5. Physicians who receive a grade of 75% or better on the post-test and complete the evaluation will receive a CME Statement of Credit.
6. All other participants who receive a grade of 80% or better on the post-test and complete the evaluation will receive a Certificate of Participation.

We encourage you to complete the Activity Evaluation to provide feedback for future programming. After submitting the evaluation, you may download the certificate immediately from the confirmation page or afterward by clicking the Download Certificate button in your confirmation email. Records of all CME/CE activities completed can be found on the "My CMEstream" page.    

CME Provider

For additional information about the accreditation of this activity, please contact PACE at contactus@partnersed.com

System Requirements

This site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended. We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Firefox, Chrome, Safari or Edge.